Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy

Next Previous
Trial Profile

A Phase I/II, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CLYM 116 (Primary)
  • Indications IgA nephropathy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NAVIGATE-2
  • Sponsors Beijing Mabworks Biotech

Most Recent Events

  • 03 Sep 2026 According to a Climb Bio media release, additional data from the ongoing phase 1 study, along with initial results from the Mabworks phase 1 healthy-volunteer portion of this study, are expected to be presented at an upcoming medical meeting in the fourth quarter of 2026.
  • 03 Sep 2026 According to a media release from Beijing Tianguangshi Biotechnology, the phase 2 NAVIGATE-2 trial in IgA nephropathy is ongoing, with the Q12W regimen intended to advance into phase 3. Initial data from the NAVIGATE-2 phase 2 trial are expected in the first half of 2027.
  • 06 Aug 2026 According to a Climb Bio media release, Mabworks anticipate initial Phase 1 data at an upcoming medical meeting, and initial Phase 2 data in 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top